Drop in Mortality Seen With AChEI, Memantine in Dementia With Lewy Bodies
Risk for death, unplanned hospital admission significantly lower for those taking AChEIs only or taking AChEIs and memantine (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - December 14, 2022 Category: Psychiatry Tags: Neurology, Pharmacy, Psychiatry, Geriatrics, Journal, Source Type: news

Drop in Mortality Seen With AChEI, Memantine in Dementia With Lewy Bodies
WEDNESDAY, Dec. 14, 2022 -- For patients with dementia with Lewy bodies (DLB), treatment with acetylcholinesterase inhibitors (AChEIs) and/or memantine is associated with reduced hospital admissions and mortality, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 14, 2022 Category: Pharmaceuticals Source Type: news

Off-Label Use of Dementia Meds Tied to Lower Mortality in DLB Off-Label Use of Dementia Meds Tied to Lower Mortality in DLB
Off-label use of acetylcholinesterase inhibitors and memantine is associated with better survival following hospitalization for patients with dementia with Lewy bodies (DLB).Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - December 6, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Effect of memantine on prolonging safe driving in early AD: a pilot study - Holland PJ, Tappen RM, Newman DO, Freeman-Costin KC, Fisher LJ.
BACKGROUND: To determine the feasibility of conducting an RCT on the potential effectiveness of memantine hydrochloride in prolonging safe driving in mild AD. METHODS: A placebo-controlled, double blind randomized trial was conducted. Forty-three i... (Source: SafetyLit)
Source: SafetyLit - December 18, 2021 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Role of Memantine in the Prophylactic Treatment of Migraine Role of Memantine in the Prophylactic Treatment of Migraine
Memantine has been used off-label for the prevention of episodic migraine. Does current evidence support its efficacy and safety for migraine prophylaxis?Headache (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 8, 2021 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Author Q & A: Ketamine as a treatment for depression
In this interview with Doctoral Researcher Rebecca Dean and Professor Andrea Cipriani we learn more about two reviews investigating the use of ketamine as a treatment for depression recently published through Cochrane ’s Common Mental Disorders Group.Tell us about this Cochrane ReviewThis review is an update of a Cochrane review published in 2015, investigating the use of ketamine and other glutamate receptor modulators as a treatment for unipolar depression (also known as major depressive disorder).Since 2015, a lot of research has been published in this area and the FDA has recently licensed esketamine (Spravato) for u...
Source: Cochrane News and Events - October 7, 2021 Category: Information Technology Authors: Lydia Parsonson Source Type: news

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia
Wednesday, February 3, 2021 (Source: Cochrane News and Events)
Source: Cochrane News and Events - February 3, 2021 Category: Information Technology Authors: Lydia Parsonson Source Type: news

Memantine misuse and social networks: a content analysis of internet self-reports - Natter J, Michel B.
PURPOSE: Memantine is a N-methyl-D-aspartate (NMDA) receptor antagonist currently used for moderate-to-severe Alzheimer's disease. Although the risk of memantine abuse is very low, other NMDA receptor antagonists, such as phencyclidine and ketamine, are we... (Source: SafetyLit)
Source: SafetyLit - July 4, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

ANI Pharmaceuticals Announces FDA Approval of Memantine Hydrochloride Extended-Release Capsules
BAUDETTE, Minn., March 2, 2020 -- (Healthcare Sales & Marketing Network) -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Foo... Biopharmaceuticals, Neurology, FDA ANI Pharmaceuticals, Memantine, Alzheimer's (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 2, 2020 Category: Pharmaceuticals Source Type: news

Class 4 Medicines Defect Information: Memantine 10mg Film-Coated Tablets, PL 20416/0260
Crescent Pharma Ltd has informed the Medicines and Healthcare products Regulatory Agency (MHRA) of... (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - February 25, 2020 Category: Drugs & Pharmacology Source Type: news